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1 Abbreviations 
ADE Adverse drug event 
ADR Adverse drug reaction 
ANZPIC Australian and New Zealand Paediatric Intensive Care Registry 
AKI Acute kidney injury 
ALAT Alanin-amino-transferase 
ASAT Aspartat-amino-transferase 
ATC Anatomical therapeutical chemical classification 
CI Confidence Intervall 
CPOE Computerized physician order entry 
CRP C-reactive protein 
die Day 
eGFR Estimated glomerular filtration rate 
f Female 
g Gram 
GFR Glomerular filtration rate 
GGT Gamma-glutamyl-transferase 
ICU Intensive care unit 




MDSi Minimal data set of the Swiss Society of Intensive Care Medicine 
mg Milligram 
mcg Microgram 
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mcmol Micromole 
mmol Millimol 
ME Medication error 
MODS Multiple organ dysfunction syndrome 
MPE Medication prescribing error 
NCCMERP National Coordinating Council for Medication Error Reporting and 
Prevention 
NSAID Non-steroidal anti-inflammatory drugs 
PCNE Pharmaceutical Care Network Europe 
PICU Paediatric intensive care unit 
PIM Paediatric Index of Mortality Score 
pRIFLE Paediatric modified Risk, Injury, Failure, Loss, End-Stage criteria for 
renal failure 
RR Risk ratio 
SD  Standard Deviation 
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2 Introduction 
The issue of medication safety has received considerable attention in the last few 
years. Especially drug related problems (DRP) are a major safety issue. Several 
studies noted that the risks associated with the administration of drugs are high as it 
causes substantial mortality, morbidity and additional healthcare costs [1-3]. Hospital 
pharmacists are best placed to oversee the quality of the entire drug distribution, 
preparation and administration chain and can fulfil an important role in improving 
medication safety. Due to this fact, the pharmacist can improve the quality of 
pharmacotherapy. 
Drug-related problems 
The identification, prevention and resolution of DRPs are the core processes of 
pharmaceutical care. As defined by the Pharmaceutical Care Network Europe 
(PCNE), a DRP is an event or circumstance involving drug therapy that actually or 
potentially interferes with the desired health outcomes [4]. The term DRP contains 
adverse drug events (ADEs), adverse drug reactions (ADRs) and medication errors 
(ME). ADEs are defined as problems related to the use of a drug, but without 
evidence of the causality [5]. The definition of the term ADR covers noxious and 
unintended effects resulting not only from the authorised use of a medicinal product 
at normal doses, but also from MEs and uses outside the terms of the marketing 
authorisation, including the misuse and abuse of the medicine [6]. MEs are defined 
as problems that involve a mistake in the process from the prescribing to the 
administration of the drug [5]. 
Children are thought to be at higher risk of DRPs than adults due to their physiology 
and immature mechanism of drug metabolism [7]. Some other factors that make 
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children vulnerable include the need of dosing calculation, the problems related to 
the inappropriate confection of drugs for children (with the need for special dilutions 
and manipulations of the drugs before application) and the high frequency of 
unlicensed and off label drug prescriptions [8].  
 
Despite the awareness that children are at increased risk for DRPs, little is known 
about the epidemiology of these problems and where the gaps remain in our present 
knowledge. We undertook three studies to help provide a better understanding of (1) 
acute kidney injury as a possible ADE, (2) prescribing errors, which are considered 
as a subgroup of MEs and (3) high drug exposure as an important medication safety 
issue.   
 
(1) Acute kidney injury as a possible adverse drug event 
Acute kidney injury (AKI) is a devastating problem in critically ill children associated 
with an increased morbidity and mortality [9-11]. However AKI has not only been 
associated with increased mortality, but also with increased length of hospital stay, 
increased healthcare resource use and increased costs [10, 12-14]. In addition 
various drugs are currently being taken into consideration as possible causal factors 
of AKI in children [15]. Importantly, nephrotoxic medication exposure is becoming 
more prevalent as a primary cause of AKI, comprising approximately 16% of all 
paediatric inpatient causes of AKI [16]. The risk of developing AKI when any 
nephrotoxic medication is initiated and the additive risk of AKI development with 
multiple nephrotoxic medications are unknown. The outcomes of paediatric patients 
may be improved by identifying patients at risk for medication associated AKI. 
However, the true incidence of drug-induced nephrotoxicity is difficult to determine 
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because of the complexity of the clinical situation in critically ill children [17-19]. 
Nevertheless, this case control study may help to identify specific types of 
nephrotoxic drugs associated with a risk of developing AKI. 
  
(2) Medication prescribing errors as a subgroup of medication errors 
Medication errors (MEs) are common. Especially patients admitted to an intensive 
care unit (ICU) are at high risk for medication errors due to the critical nature of their 
illnesses, polypharmacy and the use of high-risk drugs [20]. Limited evidence 
suggests that the prevalence of ME and corresponding harm may be higher in 
children than in adults [21]. In addition, the majority of theses MEs are errors in 
prescribing [22]. Medication prescribing errors (MPEs) are much more important in 
children than in the adult population. In paediatric prescribing, more calculations are 
required as nearly all drugs have varying doses depending on the weight and/or 
bodysurface of the child. Additionally, drugs are often used unlicenced or off-label 
leading to less clear dosing guidance [23]. There have been two studies investigating 
paediatric prescribing errors in the UK, one showing an error rate of 5.3% of all 
medication orders and the other was not presenting an error rate [24, 25]. Other 
paediatric studies in USA and Australia found that prescribing errors occur in 0.4 to 
1.9% of all written medication orders [26, 27] and cause harm in about 1% of all 
inpatients [24]. Ghaleb et al [28] carried out a prospective review of drug charts by 
pharmacists and researchers across five London hospitals over a 2-week period. 
This study found a prescribing error rate of 13%. Therefore, in order to improve 
patient-safety we need to know more about the frequency, the types and the severity 
of these MPEs. 
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(3) The number of drugs as an important issue of medication safety 
The possibility that more care may also cause harm is unexpected and received little 
attention in the past [29]. Especially in intensive care units (ICU), patients receive 
twice as many drugs as patients in general care units and are therefore at high risk of 
an ADE or an ADR [30]. But principally the drug use in children should be clearly 
considered because the frequency of unlicensed and off label drug prescriptions is 
high [22]. In addition, the paediatric intensive care unit (PICU) is a setting where 
children are seriously ill and multiple drugs are prescribed. Some studies showed 
that particularly young children are at risk for a high drug exposure [31-34].  
Our analysis should give some indications of patient related factors correlating with 
and probably influencing drug prescription in paediatric intensive care and the 
independent association of the number of drugs on the immediate patient outcome.  
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3 Aims of the Thesis 
The general aim of this thesis was to point out several important issues relating to 
medication safety in children. 
The first focus of this thesis was to assess a potential association between drug use 
and the risk of developing acute kidney injury (AKI) in critically ill children with no pre-
existing renal insufficiency at the University Children’s Hospital Zürich.  
The second focus of this thesis was to analyse medication prescribing errors (MPE) 
in critically ill children in the paediatric intensive care unit (PICU) at the University 
Children’s Hospital Zürich. The specific objective of this study was to analyse the 
frequency, the type and the severity of such errors, with a view to reduce MPE and to 
improve patient safety.  
The third focus of this thesis was to show the association between the number and 
profile of drugs applied in the first 24 hours of admission to PICU and socio-
demographic, diagnostic and severity of illness parameters. The analysis should 
provide information on patient related factors correlating with and probably 
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4 Methods, Results and Discussion 
The content of this dissertation is based on the subject of three publications. Thus, 
the following pages contain these three papers starting with the case-control study 
‘drugs as risk factors of acute kidney injury in critically ill children’, continuing with the 
analysis of medication prescribing errors in critically ill children and ending with a 
retrospective study analysing the number and profile of ordered drugs and their 
association with socio-demographic, diagnostic and severity of illness parameters. 
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Abstract 
Background 
Acute kidney injury (AKI) is a serious condition in critically ill children. Nephrotoxic 
medication exposure is a common contributing factor to AKI, but little literature is 
available in paediatrics. The aim of the study was to assess a potential association 
between drugs and the risk of developing AKI.  
Methods 
We performed a retrospective case-control study in a paediatric intensive care unit 
(PICU). Cases were patients who developed AKI during PICU stay. Patients without 
AKI served as controls and were matched to cases on age category and gender in a 
one to one ratio.  
Results 
100 case-control pairs were included. Cases were not statistically different from 
controls with regard to median weight and main diagnoses, but differed with regard to 
the need of mechanical ventilation, the severity of illness, and the median length of 
PICU stay. Multivariate models revealed a statistically significantly higher risk of 
developing AKI for patients treated with Metamizol, Morphine, Paracetamol and 
Tropisetron. A similar risk could be shown for medication groups, namely 
glucocorticoids, betalactam antibiotics, opioids and non-steroidal anti-inflammatory 
drugs. 
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Conclusion 
The results suggest that drugs are associated with acute renal dysfunction in critically 
ill children, but the multifactorial causes of AKI should be kept in mind. 
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Introduction 
Acute kidney injury (AKI) is a serious condition in critically ill patients. Little literature 
is available on the association between drug therapy and AKI in the setting of 
paediatric intensive care.  
AKI continues to represent a very common and potentially devastating problem in 
critically ill children. Recent studies have revealed that AKI may be an independent 
risk factor for mortality in critically ill children [1-3]. 
Furthermore, AKI has not only been associated with increased mortality, but also with 
increased length of hospital stay, increased healthcare resource use and increased 
costs in critical illness [4-7]. 
Previous paediatric studies have shown that the incidence of AKI ranges from 7% to 
25% depending on the definition of AKI used and the population studied [8]. The 
variability in incidence and mortality rates of AKI is in part because no consensus 
exists regarding which definition should be used [1, 9]. Nonetheless, the available 
data suggest that the incidence of AKI in asphyxiated neonates is high, that non-
oliguric AKI is common, and that AKI portends poor outcomes [10-14]. 
In addition various drugs are currently being taken into consideration as possible 
causal factors of AKI in children. Predisposing factors such as age, 
pharmacogenetics, underlying disease and concomitant medication determine and 
influence the severity of nephrotoxic insult [15]. The overall contribution of drugs to 
renal injury in the paediatric intensive care unit (PICU) is unknown because of the 
complexity of the clinical situation in critically ill children [8, 10, 16, 17]. 
Importantly, nephrotoxic medication exposure is becoming more prevalent as a 
primary cause of AKI, comprising approximately 16% of all paediatric inpatient 
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causes of AKI [18]. Health outcomes of paediatric patients may be improved by 
identifying patients at risk for medication associated AKI. Additionally medication 
selection may need to be altered to prevent poor outcomes or minimise risk caused 
by nephrotoxic medications[18]. 
The aim of the current study is (1) to assess a potential association between drug 
use and the risk of developing AKI in critically ill children with no pre-existing renal 
insufficiency, and (2) to identify the specific types of nephrotoxic drugs associated 
with a high risk of developing AKI. 
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Methods 
Study population, data source and data categorisation 
We performed a retrospective hospital-based case control study to determine the 
odds of medication exposure in critically ill children who developed AKI in the PICU 
at the University Children’s Hospital in Zurich during 2010. The PICU is divided into a 
general PICU (9 beds) and a cardiac PICU (9 beds).  
The study has been approved by the local Ethics Committee.  
All patients who were admitted to the PICU between April and December 2010 were 
eligible to be included into the study. Demographic parameters (sex, age and weight) 
and factors relating to severity of illness (length of PICU stay, mechanical ventilation, 
Paediatric Index of Mortality 2 (PIM2)) [19] were surveyed by means of the minimal 
data set (MDSI) of the Swiss Society of Intensive care [20]. Information on drugs 
prescribed during PICU stay (according to the anatomical therapeutical chemical 
(ATC) classification), laboratory parameters (serum creatinine, albumine, aspartate-
amino-transferase (ASAT), alanine-amino-transferase (ALAT), C-reactive protein 
(CRP)), main diagnosis (according to the Australian and New Zealand Paediatric 
Intensive Care Registry (ANZPIC) Diagnostic Codes) [21], were obtained from the 
electronic patient records or the order sheets. All medication orders were included in 
this analysis. 
Age was categorised into five different age groups: neonates (0-4 weeks), infants (1-
12 months), toddlers (1-4 years), children (5-11 years) and adolescents (> 12 years).  
The main diagnoses were categorised into the following groups: airway, 
cardiovascular, miscellaneous, neurological, or post procedural. Patients who were 
sent to the PICU after cardiac surgery were classified as post procedurals. Patients 
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who were first in the PICU and had then a cardiac surgery were classified as 
cardiovascular.  
Paediatric Index of Mortality Score (PIM2) was categorised into three different strata 
related to the expected risk of mortality in percentages: category 1 (0-0.99%), 
category 2 (1.0%-9.99%) and category 3 (10%-100%) [22]. 
Medication exposure was defined as any medication a study subject received before 
developing AKI. Number of drugs was defined as the number of different drugs that a 
study subject received before developing AKI.  
Case and Control definition 
Cases were defined as any patient hospitalised in the PICU who developed an AKI 
described by stage ‘Risk’ or worse using the pediatric Risk, Injury, Failure, Loss, End-
Stage Kidney Disease (pRIFLE) definition (table 1) [3].  
Table 1: AKI Definition using the estimated glomerular filtration rate criteria of the pRIFLEi definition 
AKI Classification Estimated glomerular filtration rate (eGFR) criteria 
Risk (R) Decrease by 25% 
Injury (I) Decrease by 50% 
Failure (F) Decrease by 75% or eGFR < 35 mL/min/1.73m2 
 
The lowest estimated glomerular filtration rate (eGFR) was calculated using the 
updated Schwartz formula and the peak Serum creatinine [23]. Baseline eGFR was 
assumed using the filtration rate by Guignard and Gouyon (table 2) [24].  
Table 2: Baseline estimated glomerular filtration rate 
age Baseline eGFR (mL/min/1.73 m2) 
0 - 4 weeks 13 
≥ 1 month - 3 months 50 
≥ 3 months - 12 months 100 
≥ 1 year 120 
 
The maximal percent eGFR drop during treatment was calculated ((Baseline eGFR – 
lowest eGFR)/Baseline eGFR * 100) to determine the worst pRIFLE AKI category. 
                                                 
i The original pRIFLE definition also comprises urine output which was not assessed in this study. The 
categories ‚Loss‘ and ‚End Stage Kidney Disease‘ of the pRIFLE definiton, representing renal dysfunction of 
prolonged duration, were not assessed for this study. 
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Controls (no renal impairment) were matched to cases in a 1:1 ratio on age category 
and gender. Controls were recruited from the patients hospitalised during the same 
time period in PICU. Serum creatinine levels were measured for cases as well as for 
controls. If more than one control met matching criteria, the control with the nearest 
admission date to the case was selected.   
Statistical analysis 
Demographic variables were summarized using descriptive statistics. Differences 
between cases and controls were analysed using Fisher’s exact test for categorical 
variables and Wilcoxon test (also known as Mann-Whitney U test) for continuous 
variables, because assumptions of normality could not always be satisfied. 
Continuous variables were expressed as median, categorical variables were 
expressed as proportions (%). 
Multivariate conditional logistic regression models were then developed to evaluate 
the independent association between the administered drugs and the risk of AKI, 
controlling for potential confounding variables such as PIM2 score, length of PICU 
stay, mechanical ventilation and weight. 
In a second step, we classified the most frequently administered drugs in eight 
pharmacologically different groups (drugs for cardiac stimulation, diuretics, 
glucocorticoids, betalactam antibiotics, opioids, non-steroidal anti-inflammatory drugs 
(NSAID), benzodiazepines and antithrombotic drugs).  
We then ran a multivariate model including the medication groups, adjusted as well 
for the above mentioned potential confounding variables.  
Statistical significance was defined as p ≤ 0.05. Odds ratios (OR) are presented with 
a 95% confidence interval (CI). All of the data analyses were conducted using the 
software program SAS, version 9.3 (SAS Institute, Inc, Cary, NC).
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Results 
Characteristics of the patients 
A total of 412 patient admissions were identified during the study period. Among 
these 412 patients 100 cases with AKI were identified, and the same number of 
matched controls resulting in a dataset of 200 patients. Male and female cases and 
controls were evenly distributed (50%). The case data set was not statistically 
different from the control data set in terms of median weight and main diagnoses 
(except the cardiovascular diagnosis). The detailed characteristics of the cases and 
the controls are displayed in table 3. 
As reported in table 4, the cases were statistically different from the controls with 
regard to the severity of illness described by the PIM2 Score (except PIM2 Score 
category 2) and the median length of PICU stay (4 days vs 3 days). There was no 
statistically significant difference with regard to the need for mechanical ventilation 
(73% vs 60%). 
Case-Control Study  Medication Safety in Children 
Page 24 Inauguraldissertation, University of Basel Corina Glanzmann 
Table 3: Patient characteristic of cases and controls (matching criteria: age category and gender) 
Categories Number of cases 
N = 100 
Number of controls 




    1.000 
Neonates 
(0-4 weeks) 
2  2    
Infants 
(1-12 months) 
15  15    
Toddlers 
(1-4 years) 
41  41    
Children 
(5-10 years) 
24  24    
Adolescents 
(>10 years) 
18  18    
    
Sex   1.000 
    
Male 50  50    
    
Female 50  50    
    
Weight kg kg P-Value 
    
all 14 (0.8, 82)* 15 (3, 84)* 0.414 
    
Neonates 4 (3, 4)* 6 (3, 8)* 0.667 
 (0-4 weeks)    
Infants 5 (0.8, 10)* 6 (3, 8)* 0.507 
 (1-12 months)    
Toddlers 12 (7, 30)* 14 (7, 25)* 0.062 
(1-4 years)    
Children 20 (11, 35)* 23 (16, 41)* 0.122 
(5-10 years)    
Adolescents 48 (7, 82)* 34 (4, 84)* 0.220 
(>10 years)    
Main Number of cases Number of controls P-Value 
diagnosis N = 100 N = 100  
Airway 5  7  0.766 
    
Cardiovascular 37  18  0.004 
    
Injury 12  16  0.541 
    
Miscellaneous 13  12  1.000 
    
Missings 2  3  1.000 
    
Neurological 9  14  0.375 
    
Post procedural 22  30  0.259 
N = number of patients, * = range 
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Table 4: Severity of illness parameters of cases and controls 
Categories Number of cases 
N = 100 
Number of controls 
N = 100 
P-Value 
Mechanical ventilation   0.072
Yes 73  60  
PIM2 Score   
Category 1 
(0-0.99%) 
22  43  0.003
Category 2 
(1-9.99%) 
64  50  0.151
Category 3 
(10-100%) 
14  4  0.026
   
Length of PICU stay 
(days) 
4 (0, 49)* 3 (0, 79)* 0.002
N = number of patients, * = median and range 
Drug exposure of cases and controls 
Additionally, 53% of the cases were exposed to one or more drugs before onset of 
AKI , whereas only 13% of the controls were exposed to drugs. Similarly, cases had 
a greater number of different drugs. They received a median of 3 (range 0 to 25) 
different drugs before developing AKI. Both the number of different drugs received 
and medication exposure (drugs vs. no drugs) were associated with improved 
predictability for development of AKI. 
Multivariate conditional logistic regression analysis 
We developed a „single medication model“ to analyse the association between 
various drugs and the development of AKI. Parameters were adjusted for PIM2 
score, length of PICU stay, mechanical ventilation and weight. Table 5 shows that 
patients treated with analgesics such as Metamizol, Morphine or Paracetamol and 
Tropisetron had a significantly greater odds ratio to develop AKI.   
The second model (table 6) was a „medication group model“, which evaluated the 
association (odds ratio) between the eight most frequently administered medication 
groups and the development of AKI. Adjustments were made for the same 
parameters displayed above. Four of the eight drug groups namely betalactam 
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antibiotics, glucocorticoids, NSAID and opioids were associated with a statistically 
significantly increased risk for developing AKI. The other four groups did not show 
any association with acute renal dysfunction. 
Table 5: Odds for the development of AKI: “single medication model” 







Metamizol 17 6 4.6 
(1.36; 15.6)
0.014 
Morphine 40 10 2.4 
(1.02; 6.03)
0.042 





















12 4 3.1 
(0.65; 14.4) 
0.158 
     
Benzodiazepines 8 1 5.4 
(0.58; 50.1) 
0.137 
    
Betalactam 
antibiotics 
25 10 2.3 
(1.03; 6.01) 
0.043 
     
Cardiac 
stimulation 
22 11 1.8 
(0.55; 5.58) 
0.341 
     
Diuretics 21 11 2.1 
(0.76; 5.53) 
0.158 
     
Glucocorticoids 10 1 18.5 
(1.75; 195) 
0.015 
     
NSAID 18 9 2.3 
(1.08; 6.37) 
0.027 
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Discussion 
In the current hospital-based case-control analysis we assessed the association 
between drug use and the risk of AKI in a paediatric intensive care setting. AKI-cases 
were three times more likely to be exposed to one or more drugs than the controls. In 
the wider setting of hospitalized paediatric patients, previous reports have noted that 
nephrotoxic medications are a common aetiological factor of AKI [18]. In our study, 
only few individual drugs were noted as being independently associated with the 
development of AKI in multivariate analyses. The identification of only few drugs 
associated with AKI lends support to the hypothesis that individual medication 
exposure may not be as important a risk factor for AKI than multiple medication 
exposure. Anyway, it is difficult to determine the overall contribution of drug-induced 
renal dysfunction due to the complexity of the clinical situation in critically ill patients. 
Nonetheless, a few studies revealed nephrotoxic medication groups such as NSAID, 
antibiotics, ACE-inhibitors, chemotherapeutics and diuretics [25-28]. Within our study 
population we could find evidence that some of the above mentioned drug groups are 
indeed involved in the development of AKI. In our study, children treated with NSAID 
had a two-fold higher risk (OR 2.3, 95% CI 1.08 to 6.37) of developing AKI. NSAID 
associated AKI has been previously reported in 54 infants and children in case 
reports or small case series [28]. Misurac et al. demonstrated in the largest series to 
date, that NSAIDs are a common cause of AKI in children [29].  
The multivariate analysis provided evidence for an association between some other 
drug groups and AKI risk, such as betalactam antibiotics (OR 2.3, 95% CI 1.03 to 
50.1), glucocorticoids (OR 18.5, 95% CI 1.75 to 196) and opioids (OR 3.2, 95% CI 
1.35 to 7.75). These drugs are often used in the treatment of various diseases which 
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can directly impair renal function. It is difficult, though, to distinguish between the role 
of the underlying disease the drugs are used for, and the contribution of the drug 
itself. This phenomenon called ‘confounding by indication’ could also be an 
explanation why our analysis revealed Tropisetron (OR 20.8, 95% CI 1.98 to 219) as 
a potentially nephrotoxic drug. In view of the short term nature of the recommended 
treatment regimen of Tropisetron [30] the underlying disease is probably more to the 
fore than Tropisetron itself.  
Very surprisingly, there was a significant association between Paracetamol use and 
AKI. Children who received Paracetamol had a three-fold higher relative risk (OR 3.5, 
95% CI 1.47 to 8.21) of developing AKI than children who were not treated with 
Paracetamol. Paracetamol is widely used in children because its safety and efficacy 
are well established. However, the adverse effects of Paracetamol on the kidney are 
still being investigated, and data on renal toxicity in children are limited. Shahroor et 
al. looked at toxic effects of Paracetamol in paediatric use and described two children 
who developed severe hepatic damage combined with renal insufficiency [31]. Onay 
et al. described two children admitted to their hospital with acute nonoliguric renal 
failure temporally associated with ingestion of Paracetamol at therapeutic doses [32]. 
We did not find an association between ACE-inhibitors and aminoglycoside 
antibiotics and the development of AKI, as it is described in the literature [33-35]. 
This may be related to the tight monitoring of aminoglycoside blood levels and the 
repeated creatinine measurements in children on ACE-inhibitors. 
Our study revealed that AKI-cases had an increased length of stay and mortality 
compared to AKI-free control patients. This finding is in line with various recent 
studies [36-38]. The need for mechanical ventilation was higher in cases compared 
to controls (73% vs 60%) a finding which is consistent with previously published data. 
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Akandari et al. reported that children with AKI had approximately twice the duration of 
mechanical ventilation compared to non-AKI patients [39]. The question remains 
whether these worse outcome parameters (length of stay, mortality, mechanical 
ventilation) are directly caused by AKI, or whether they are just related to increased 
co-morbid conditions which by themselves put children at increased risk for AKI. 
Recent studies suggest that the most common cause of AKI is multifactorial [37, 38, 
40]. Because of the many different factors which are associated with AKI it is very 
difficult to show the independent role of drug exposure. We tried to take into account 
the co-morbidity of the patients as a cause of AKI. In the logistic regression analysis 
we included at least some indirect measures of co-morbidity, such as severity of 
illness at admission, mechanical ventilation and length of stay. 
There are some well described populations at risk for AKI. Critically ill newborns with 
asphyxia are at great risk to develop AKI [12, 14, 40]. Furthermore, cardiovascular 
patients have been reported to be at higher risk of AKI. Our results also show a 
significant difference (P-Value 0.004) between cases and controls with regard to the 
main diagnosis cardiovascular disease, which is in accordance with the literature [39, 
41]. Factors such as the complexity of the heart defect have previously been 
identified as risk factor for renal dysfunction in children [41]. In another recent study 
by Hui-Stickle et al., cardiac diseases were present in 30% of paediatric patients 
developing AKI [36].  
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Limitations 
As with most case-control studies, matching is a difficult process and we were unable 
to match some patients on exact age, so that we matched them on age category. 
Although there could be a significant difference in age within categories, this is likely 
not clinically significant with regard to renal function. Additionally, the number of 
cases (N = 100) and the matched controls (N = 100) was rather small, which limits 
the possibility of doing subgroup analyses and which limits the interpretation of 
multivariate analyses. In our study, doses and durations of exposure to the drug 
before developing AKI were not taken into consideration.  
The definition of AKI cases was based on a simplified pRIFLE criteria. Other renal 
function variables such as urine output were not comprised as definition criteria in our 
study. Due to our small case control study we just used one AKI stage (‘Risk’ and 
worse) and did not stratify the cases into ‘Risk’, ‘Injury’ and ‘Failure’ groups because 
this would make the interpretation of the results virtually impossible due to lack of 
statistical power in the various subgroups.  
Conclusion 
The results of this case-control analysis suggest that drugs are associated with acute 
renal dysfunction in paediatric intensive care, especially some critical medication 
groups such as betalactam antibiotics, glucocorticoids, opioids and NSAIDs. It is also 
important to underline the multifactorial aetiology of AKI. Our results emphasize the 
complexity of AKI development. Therefore early recognition of drug-induced renal 
dysfunction may alleviate some of the mortality that is associated with AKI in the 
PICU.  
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Abstract 
 Medication prescribing errors (MPE) can result in serious consequences for patients. 
In order to reduce errors, we need to know more about the frequency, the type and 
the severity of such errors. We performed therefore a prospective observational 
study to determine the number and type of medication prescribing errors in critically 
ill children in a paediatric intensive care unit (PICU). Prescribing errors were 
prospectively identified by a clinical pharmacist. A total of 1’129 medication orders 
were analysed. There were 151 prescribing errors, giving an overall error rate of 14% 
(95% CI 11 to 16). The medication groups with the highest proportion of MPEs were 
antihypertensives, antimycotics and drugs for nasal preparation with error rates of 
each 50%, followed by antiasthmatic drugs (25%), antibiotics (15%) and analgesics 
(14%). 104 errors (70%) were classified as MPEs which required interventions and/or 
resulted in patient harm equivalent to 9% of all medication orders (95% CI 6.5 to 
14.4). 45 MPEs (30%) did not result in patient harm.  
Conclusion: With a view to reduce MPEs and to improve patient-safety, our data may 
help to prevent errors before they occur. 
Medication Safety in Children  Prospective observational Study 
Corina Glanzmann Inauguraldissertation, University of Basel Page 39 
Introduction 
In the current health care system, especially in neonatal and paediatric intensive 
care, medication errors are possibly an important source of morbidity [5, 15, 20, 32, 
33, 40, 41] and efforts for improvement are paramount. Medication errors range from 
those with very serious consequences to those that have little impact on the patient. 
It has thus been suggested that the severity as well as the prevalence of errors 
should be taken into account [2]. Assessing the severity of errors increases the 
quality of information regarding the clinical relevance.  
Children are a challenging group of patients because most drug dosages in 
paediatric medication are calculated individually, based on the patient’s age, weight 
or body surface area. Furthermore, the frequency of unlicensed and off label drug 
prescriptions is about 50 to 70% depending on the method of analysis and the clinical 
setting [10].This may increase the potential for medication errors. Limited evidence 
suggests that the prevalence of medication errors and corresponding harm may be 
higher in children than in adults (1.1% vs 0.35%, P< 0.001) [20]. Especially patients 
admitted to an intensive care unit (ICU) are at high risk for medication errors due to 
the critical nature of their illnesses, polypharmacy and the use of high-risk drugs [21]. 
A review estimates that 5 to 27% of medication orders for children contain an error 
somewhere along prescribing, dispensing and administering. The review also 
estimates that there are 100 to 400 prescribing errors per 1000 patients [27]. There 
have been two studies investigating paediatric prescribing errors in the UK, one 
showing an error rate of 5.3% and the other not presenting error rates [28, 7]. Other 
studies in USA found that prescribing errors occur in 0.4 to 1.9% of all written 
medications orders [5, 27, 28] and cause harm in about 1% of all inpatients [7]. 
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Ghaleb et al [18] carried out a prospective review of drug charts by pharmacists and 
researchers across five London hospitals over a 2-week period. This study found a 
prescribing error rate of 13%, which is higher than in previous studies.  
However, a major problem with interpreting quantitative prescribing error studies is 
that the definition of an error used by the researchers is often ambiguous or not given 
at all. Often studies include all medication errors and do not distinguish clearly 
enough between prescribing errors and other types of errors [18].  
The definition used in a study will impact directly on its result and therefore research 
in this area is particularly hard to interpret [16].  
In addition, the different methods of detecting prescribing errors make it difficult to 
compare studies. Higher rates of prescribing errors were detected by retrospective 
reviews compared to prospective assessments. Spontaneous reporting and the use 
of retrospective trigger tools were not accurate to detect prescribing errors. [16] 
 
To assess the epidemiology of MPEs in critically ill children may help to reduce 
serious errors in the use of prescribed drugs. Our goals were (1) to determine the 
rates of MPEs, (2) analyse the major types of errors and the drugs most commonly 
involved and (3) assess the severity of these errors. 
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Methods 
Setting, study population and data source 
We performed a prospective observational study to determine the number and type 
of medication prescribing errors in critically ill children in the paediatric intensive care 
unit (PICU) at the Children’s Hospital in Zürich during a ten months period in 2010. 
Prescribing errors were prospectively identified by one of three clinical pharmacists 
as part of their routine prescription monitoring. The pharmacist reviews every order 
before the ward round. Only medication orders on Monday, Wednesday and Friday 
were included in this analysis, because only on these days a clinical pharmacist 
participates on the ward rounds. Ward rounds are held together with a senior 
physician, two residents and two nurses. The pharmacist told the medical and 
nursing PICU team which prescribing errors occurred in order to prevent harm to the 
patient. 
The PICU is divided into a general PICU (9 beds) and a cardiac PICU (9 beds). The 
whole range of neonatal (also preterms), paediatric, surgical and cardiac surgical 
patients is admitted, excluding liver transplant patients. All up-to-date procedures are 
offered, including high-frequency oscillatory ventilation, inhaled nitric oxide (NO), 
renal replacement therapy (peritoneal dialysis and haemofiltration) and extra-
corporeal-membrane-oxygenation (ECMO). About 25% of patients are neonates, 
mainly with cardiac and/or surgical pathologies. The study has been approved by the 
local Ethics Committee.  
All patients who were admitted to the general PICU between April and December 
2010 were eligible to be included into the study. Each readmission after 24 hours 
outside PICU was considered a new and separate case. Demographic parameters 
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(sex, age and weight) and factors relating to severity of illness (length of PICU stay, 
mechanical ventilation, Paediatric Index of Mortality 2 (PIM2) [36]) were surveyed by 
means of the minimal data set (MDSi) of the Swiss Society of Intensive care [43]. 
Information on drugs prescribed during PICU stay (according to the anatomical 
therapeutical chemical (ATC) classification), laboratory parameters (serum 
creatinine, albumine, aspartate-amino-transferase (ASAT), alanine-amino-
transferase (ALAT), c-reactive protein (CRP)), main diagnosis (according to the 
Australian and New Zealand Paediatric Intensive Care Registry (ANZPIC) Diagnostic 
Codes [35]), were obtained from the electronic patient records or the order sheets.  
Age was categorised into five different age groups: neonates (0-4 weeks), infants 
(>1-12 months), toddlers (>1-4 years), children (>5-11 years), or adolescents (> 12 
years).  
The main diagnoses were categorised into the following groups: Airway, 
cardiovascular, gastrointestinal, infection, injury, miscellaneous, neurological, post 
procedural or renal [35]. 
PIM Score was categorised into three different strata related to the expected risk of 
mortality in percentages: category 1 (0-0.99%), category 2 (1.0%-9.99%), or category 
3 (10%-100%) [39]. 
Number of medications was defined as the number of different drugs that a study 
subject received during the study period except the drugs kept in reserve.  
Drugs were ordered by means of an excel order form without drug-drug interaction 
information. This order form was created by a resident of the PICU. Residents wrote 
prescriptions on a structured form using a lap-top computer at the bedside. There 
were some calculation aids, such as calculating the whole dose from the dose per 
kilogram body weight. For the preparation of continuous drips, standardised tables 
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were used, so that the residents only needed to order the amount of the medication 
per time (e.g.: adrenaline: 0.1 mcg/kg/min). All medication preparations were done by 
nurses. Regular orders, valid from 2 pm to 2 pm of the next day, were written on 
morning rounds and printed out. Additional orders, if required later than 2 pm, were 
written by hand on the back of the order form. 
Medication prescribing error definition 
For the purpose of this study, a clinically meaningful medication prescribing error 
(MPE) was defined as a prescribing decision or prescribing writing process, that 
results in an unintentional, significant reduction in the probability of treatment being 
timely and effective or increase in risk of harm, when compared with generally 
accepted practice. [4]  
Identification and classification of medication prescribing errors 
MPEs were classified according to an adapted Pharmaceutical Care Network Europe 
(PCNE) classification [30]. Only six of the eight primary domains of PCNE for causes 
of MPEs were used for the classification: drug selection (the cause of the MPE can 
be related to the selection of the drug), drug formulation (the cause of the MPE is 
related to the selection of the drug formulation), dose selection (the cause of the 
MPE can be related to the selection of the dosage schedule), treatment duration (the 
cause of the MPE is related to the duration of therapy), drug use process (the cause 
of the MPE can be related on the way the patient gets the drug administered) and 
other problems. The domain missing information (the cause of the MPE can be 
related to omitting information) was added. Additionally, sub domains were formed 
for each main domain which can be seen explanatory for the principal domains. The 
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other primary domains such as domains for problems and domains for interventions 
were not taken into account because we only wanted to classify prescribing errors.  
Classification of the dosage 
For calculation and verification of the correct drug dose the dosage booklet published 
by the Children’s Hospital Zürich in 2009 was used [11]. This booklet contains 
dosages for regulatory approved drugs, as well as information on drugs which are not 
approved, but for which evidence or at least eminence based paediatric dosages are 
available. Was the drug dose not in the range given in the booklet, then the dose was 
considered to be wrong.  
Classification of drug-drug interactions 
Drug-drug interactions occur when the effect of one drug is changed by the presence 
of another drug.  
All medication orders were screened for drug-drug interactions using the interaction 
screening program Pharmavista [13]. The program classifies the severities of drug-
drug interactions into five categories: major, moderate, minor, insignificant, or of 
unidentified source. In this study, only the categories major, moderate and minor 
were taken into account for an inappropriate drug selection/drug dose.  
Categorisation of medication prescribing errors by severity 
A classification according to the National Coordinating Council for Medication Error 
Reporting and Prevention (NCCMERP) was used [38] (Table 1). Each MPE was 
independently scored for error severity by a clinical pharmacist and by a senior 
intensive care physician. Any disagreements were resolved by a senior clinical 
pharmacist. 
Medication Safety in Children  Prospective observational Study 
Corina Glanzmann Inauguraldissertation, University of Basel Page 45 
Table 1: Severity of medication prescribing error 
iMajor divisions Subcategory Description 
Error, no harm Category A Circumstances that have the capacity to cause 
error 
Category B Error did not reach the patient, because it was 
intercepted before or during administration process 




Category D Error reached the patient and required monitoring 
to confirm that it resulted in no harm to the patient 
and/or required intervention to preclude harm 
Error, preventable ADE Category E Error may have contributed to or result in 
temporary harm to the patient and required 
intervention 
Category F Error may have contributed to or result in 
temporary harm to the patient and required initial or 
prolonged hospitalisation 
 Category G Error may have contributed to or resulted in 
permanent harm 
Category H Error required intervention necessary to sustain life 
 
Statistical analysis 
Demographic variables were summarized using descriptive statistics. Differences 
between patients with MPEs and patients without MPEs were analysed using Fishers 
exact test for categorical variables and Wilcoxon test (also known as Mann-Whitney 
U test) for continuous variables, because assumptions of normality could not always 
be satisfied. Continuous variables were expressed as median, categorical variables 
were expressed as proportions (%). 
The error rate was calculated as the percentage of errors relative to total drug orders 
with 95% confidence interval (CI).  
In a second step, we classified the most frequently administered drugs in nine 
different groups (drugs for cardiac stimulation, diuretics, antiasthmathics, antibiotics, 
antiepileptics, antimycotics, analgesics, antihypertensives, or nasal preparations). 
                                                 
i Classification according to the National Coordinating Council for Medication Error Reporting and 
Prevention (NCCMERP) [24] 
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We then calculated proportions of errors attributable to given medication groups with 
95% CI. 
All of the data analysis were conducted using the software program SAS, version 9.3 
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Results 
Number and rates of medication prescribing errors 
A total of 153 patients and 1’129 medication orders were analysed throughout the 
study period. There were 151 prescribing errors, giving an overall error rate of 14% 
(95% CI 11 to 16). Medication orders from 65 patients contain one or more MPEs. 
Dose selection errors were the most common type of MPEs with an error rate of 
6.6% (95% CI 5.3 to 8.3) followed by drug selection errors with an error rate of 2.1% 
(95% CI 1.3 to 3.0). A list of the most frequent MPEs and their associated error rates 
is given in table 2. 
Table 2: Number and error rates of medication prescribing errors 
Categories Number of MPEs 
(N(%)) 
Error rates  
(%) 




151 (100) 14 11; 16 
    
Dose selection 75 (50) 6.6 5.3 ; 8.3 
 
Dose too high 22 (15) 1.9 1.2 ; 2.9 
Dose too low 17 (11) 1.5 0.9 ; 2.4 
    
Drug formulation 
 
7 (4.6) 0.6 0.2 ; 1.3 
    
Drug selection 
 
23 (15) 2.1 1.3; 3.0 
pharmacodynamic 
interaction 
9 (6.0) 0.8 0.4 ; 1.5 
pharmacokinetic 
interaction 
11 (7.3) 1.0 0.5 ; 1.7 
Missing information 
 
21 (14) 1.9 1.2; 2.8 
Missing drug formulation 16 (11) 1.4 0.8; 2.3 
Other Problems 
 
18 (12) 1.6 0.9; 2.5 
Treatment duration 0 0 0; 0.3 
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Drug categories associated with MPEs 
The involvement of medication groups according to the ATC in MPEs is shown in 
table 3. The medication groups with the greatest proportion of MPEs were 
antihypertensives, antimycotics and drugs for nasal preparation with error rates of 
each 50%, followed by antiasthmatic drugs (25%), by antibiotics (15%) and by 
analgesics (14%). 
Table 3: Medication groups associated with medication prescribing errors 











301 43 14 11; 19 
Antiasthmatics 
 
20 5 25 8.7; 49 
Antibiotics 
 
130 19 15 9.0; 22 
Antiepileptics 
 
111 18 16.2 9.9; 24 
Antihypertensives 
 
14 7 50 23; 77 
Antimycotics 
 
6 3 50 12; 88 
Diuretics 
 
39 6 15 5.9; 31 
 
Severity of medication prescribing errors 
There was a high grade of accordance (96%) between the senior physician and the 
clinical pharmacist concerning the classification of the severity of the MPEs. Only six 
errors had to be solved by the senior pharmacist. The distribution of the severity 
ratings for MPEs showed that 104 errors (70%) were classified as MPEs which 
required interventions and/or resulted in patient harm (severity category D to H) 
equivalent to 9% of all medication orders (95% CI 6.5 to 14.4). 47 MPEs (30%) did 
not result in patient harm (severity categories A, B and C). The detailed distribution of 
the severity ratings is shown in table 4.  
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Table 4: Classification of medication prescribing errors regarding severity 
Major  
divisions 
Subcategory Number of 
MPEs  
(N (%)) 
Error rates (%) 95% CI for 
error rates 
Error, no harm 
 
Category A 8 (5) 0.5 0.2 ; 1.2 
Category B 19 (12) 1.4 0.8 ; 2.3 
 
 
Category C 20 (13) 1.5 0.8; 2.4 
Error, potential 
preventable ADE 
Category D 81 (54) 7.0 5.6 ; 8.6 
Error, preventable 
ADE 
Category E 19 (13) 1.5 0.9 ; 2.4 
Category F 1 (1) 0.0 0.0 ; 2.5 
 
 
Category G 2 (1) 0.0 0.0 ; 0.6 
Category H 1 (1) 0.0 0.0 ; 0.5 
 
Demographic differences in patients with and without MPEs 
In general, demographic characteristics differed little between patients with or without 
MPEs . In particular, there were no differences regarding age, gender, weight (except 
for the category neonates) and main diagnoses (table 5).  
However, as reported in table 6, the MPE-patient group was different from the group 
without MPEs with regard to the severity of illness described by the median length of 
PICU stay (7 days vs 3 days), the median length of mechanical ventilation (31 hours 
vs 2.7 hours), and the median number of prescribed drugs (9 drugs vs 5 drugs).   
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Table 5: Characteristics of patients with and without medication prescribing errors 
Categories All 
 
N = 153 
Patients  
with MPE 
N = 65 
Patients  
without MPE 




   0.499
Neonates 47 (31%) 17 (26%) 30 (34%) 
Infants 31 (20%) 16 (25%) 15 (17%) 
Toddlers 25 (16%) 9 (14%) 16 (18%) 
Children 21 (14%) 8 (12%) 13 (15%) 
Adolescents 29 (19%) 15 (23%) 14 (16%) 
Sex 
 
   0.311
Male 
 
97 (63%) 38 (58%) 59 (67%) 
Female 
 
56 (37%) 27 (42%) 29 (33%) 
Weight 
 
Kg kg kg P-Value 
all 9.5 (0.8, 84) 9.5 (0.8, 84)* 9.2 (1.3, 72)* 0.602
Neonates 3.0 (0.8, 8.4)* 2.5 (0.8, 4.2)* 3.1 (1.3, 8.4)* 0.050
Infants 6.4 (1.3, 10)* 6.4 (1.3, 9.5)* 6.4 (2.8, 10)* 0.984
Toddlers 14 (10, 30)* 14 (11, 30)* 13 (10, 17)* 0.649
Children 23 (16, 41)* 26 (16, 41)* 22 (16, 25)* 0.405
Adolescents 46 (14, 84)* 49 (18, 84)* 39 (14, 72)* 0.570
Main  
diagnosis 
   0.560
Airway 
 
32 (21%) 14 (22%) 18 (21%) 
Cardiovascular 
 
8 (5.2%) 5 (7.7%) 3 (3.4%) 
Gastrointestinal 
 
14 (9.2%) 7 (11%) 7 (8.0%) 
Infection 
 
2 (1.3%) 0 (0%) 2 (2.3%) 
Miscellaneous 
 
28 (18%) 15 (23%) 13 (15%) 
Missings 
 
2 (1.3%) 1 (1.5%) 1 (1.1%) 
Neurological 
 
21 (14%) 7 (11%) 14 (16%) 
Post  
procedurals 
29 (19%) 9 (14%) 20 (23%) 
Renal 
 
5 (3.3%) 3 (4.6%) 2 (2.3%) 
N = number of patients, * = median with range 
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Table 6: Severity of illness parameters of patients with and without medication prescribing errors  
Categories All 
 
N = 153 
Patients  
with MPE 
N = 65 
Patients  
without MPE 




91 (60%) 42 (65%) 49 (56%) 0.318
Length of mechanical 
ventilation (hours) 
6.5 (0, 2762)* 31 (0, 2762)* 2.7 (0, 766)* 0.003
PIM2 score    0.055
Category 1 
(0-0.99%)
57 (37%) 25 (38%) 32 (36%) 
Category 2 
(1-9.99%)
80 (52%) 29 (45%) 51 (58%) 
Category 3 
(10-100%)
16 (11%) 11 (17%) 5 (6%) 
   
Length of PICU 
stay(days) 
4 (1, 116)* 7 (2, 116)* 3 (1, 20)* <0.001
Number of 
medications 
6 (1, 29)* 9 (1, 29)* 5 (1, 15)* <0.001
N = number of patients, * = median and range 
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 Discussion 
The findings of our study support the notion that MPEs occur frequently with an 
overall error rate of 14%, a proportion which is higher than the one reported in adults 
of a tertiary care teaching hospital [26]. Much has been written on the importance of 
medication errors in paediatrics and in particular on prescribing errors [3, 9, 34, 17]. 
The error rate of 14% in the current study population is comparable to other 
published data [31, 6], even though a direct comparison of error rates across various 
studies is difficult due to variations in the definitions used and in the methodology. 
Davis [8] recently pointed out that reaching a generally accepted definition is difficult. 
The errors reported in our study were all identified by a pharmacist. Other studies 
have used reviews based on medical notes and have focused on those errors that 
resulted in patient harm [34, 24, 23]. We do not know whether the errors that result in 
patient harm differ substantially from those that are identified before harm can result.  
The main prescription error in our study was wrong dosing (overdosing or 
underdosing), with an error rate of 50% of all prescribing errors. This is in line with 
findings of most previous studies [15, 9, 25, 42]. The frequent need for dose 
calculations required in paediatrics for weight based dosing is most likely an 
important factor contributing to the high rates of dosing errors.  
Other authors have found that incomplete medication orders are the most frequent 
prescribing error [18]. In our study missing information (error rate 14%) was located 
on third place. The reason for this discrepancy could be that in the other studies data 
were generally gathered on manual prescribing systems, whereas we gathered data 
from a “half-electronic” order form. 
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The second most common MPE in our study was the wrong selection of the drug 
(error rate 15%) potentially resulting in a drug-drug interaction. Risk factors for this 
may include the use of multiple drug therapies in critically ill children with multisystem 
disorders, making drug-drug and also drug-patient interactions more likely.  
All these errors were more likely to occur among children with longer stay and 
greater medication exposure than for children with shorter stay and/or requiring fewer 
drugs. The association between length of stay and MPE may be explained by two 
different scenarios: (1) the longer the PICU stay the greater risk of a prescribing 
error; or (2) due to a MPE the PICU stay could be prolonged. It also appears that 
these errors could be a consequence of disease severity where the cases were more 
complicated and the prescription complex.  
MPEs occurred across many different main diagnoses and were associated with a 
wide range of drugs. In our study antihypertensives, antimycotics and drugs for nasal 
preparation (e.g. Oxymetazolin Nasal Sprays) were most commonly involved in 
MPEs with an error rate of 50% each. These findings are not consistent with other 
published paediatric studies, where antibiotics, steroids, anticoagulants and 
hormones were the drugs most commonly related to MPEs [5, 26, 22, 1, 19]. These 
differences suggest that MPEs found in a PICU cannot be generalized to other 
children wards, and that different definition of MPEs result in differing rates of errors. 
Additionally, drugs less frequently prescribed by physicians such as antimycotics 
(only 6 orders out of 1’129 medication orders), drugs for nasal preparation (12 of 
1’129) and antihypertensives (14 of 1’129) are less known and therefore more prone 
to errors. Another reason for the high error rate of antihypertensives may be related 
to the fact that this medication group is subjected to frequent changes in dosing, 
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which makes the prescribing process even more difficult. Overall, these drug 
categories should be emphasized in the ongoing education of the entire team. 
In our study, analgesics were the medication group with the greatest number of 
MPEs (43 errors, 14%). These were the most frequently prescribed drugs in our 
PICU, and it is therefore not surprising that they accounted for more errors than other 
groups. 
Antibiotics were the second most commonly prescribed medication group in our 
study and therefore also often involved in MPEs (error rate 15%). Nevertheless, error 
rates in other studies were often higher than 15%. The percentages in previous 
studies were as follows: Folli et al. 36% [15]; Struck et al. 34% [37]; Lesar et al. 40% 
[26] and Ross et al. 44% [33]. However, these studies cannot be directly compared to 
our study because they focussed on medication errors or interventions rather than on 
MPEs. Paediatric patients are important targets for efforts aiming at reducing 
unnecessary antibiotic use [37, 12].  
With regard to error severity, our results showed that harmful or potentially harmful 
errors accounted for 66% of all MPEs. Although a direct comparison with other 
studies is hampered by differences between clinical settings, study designs and 
outcome definitions, we found studies which showed a similar proportion of harmful 
or potentially harmful errors [21, 29]. Other authors have found lower percentages, 
ranging from 17% to 36% [15, 14]. The estimation of severity of MPEs in our study 
was sometimes difficult. This is primarily because such classifications are rarely 
available in the literature. Therefore, the determination of severity was somewhat 
subjective. None of the studies mentioned any harmful effects on the patients, 
probably because the errors were corrected prior to administration.  
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Limitations 
This study has several limitations. First, as a single-center study, the findings reflect 
the situation at only one specific PICU, which may reduce the generalizability of our 
findings to other clinical settings. Second, the errors reported here were all identified 
and classified by a clinical pharmacist who gave a feedback to the physician during 
the round which could introduce a bias into the study. Clinical pharmacists routinely 
analysed drug charts only on Monday, Wednesday and Friday and we cannot 
exclude the possibility of undetected MPEs, hence underestimating the incidence of 
MPEs per patient. However, this would not affect the incidence of MPEs per 
medication orders which we described in our study. Furthermore, we did not test for 
interobserver reliability between the pharmacists, but all pharmacists were 
experienced in clinical pharmacy and followed the same guidelines. Nevertheless, 
further work is needed to establish the reliability of the identification and 
documentation of prescribing errors by pharmacists. Third, most of the prescribers in 
our study were residents. It is unknown whether resident prescribing patterns are 
different from non-resident prescribers. Forth, we focused on incidence and 
characteristics of MPE’s, as a basis for the introduction of preventive measures. In 
future studies, the mechanisms leading to MPE’s should be analysed, such as 
human factors, sources for drug choice and dosing, interface between prescriber and 
prescription. 
Conclusion 
Our analysis of MPEs revealed that prescribing errors occurred in 14% of all 
prescriptions of this PICU. The most frequent errors were wrong dose selection 
(50%), wrong drug selection (15%), and missing information (14%). By evaluating the 
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types of MPEs and by analysing patient characteristics and medication groups most 
commonly involved, we were able to identify risk factors for MPEs. At high risk for 
MPEs were children who received medication groups such as antihypertensives, 
antimycotics, drugs for nasal preparation, antiasthmatics, antibiotics and analgesics. 
Long PICU stay and the need for long mechanical ventilation were additional risk 
factors.   
With a view to reduce MPEs and to improve patient-safety, our data may help to 
prevent errors before they occur. In view of the importance of dosing errors, it seems 
to be necessary to strengthen the presence of clinical pharmacists as a key element 
in preventing prescribing errors and reducing patient harm. Even in settings with less 
resources, a clinical pharmacist can play an important role in enhancing medication 
safety, particularly in paediatric patients where calculations are often more complex.  
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Abstract 
Purpose 
The number of drugs applied to a patient is an important parameter of medication 
safety. The aim of this study was to evaluate the association between the number 
and profile of drugs applied in the first 24 hours of paediatric intensive care unit 
(PICU) and socio-demographic, diagnostic and severity of illness parameters. 
Methods 
A retrospective observational study was performed to determine the number and 
profile of drugs and their association with socio-demographic, diagnostic and severity 
of illness parameters. Number of drugs was defined as the number of different drugs 
that a study subject received during the first 24 hours. 
Results 
During the study period, 1751 medication orders in the first 24 hours were included. 
The patients received a median of 4 (range 1; 25) different drugs. The most 
frequently prescribed drug groups were analgesics without opioids (19%), opioids 
(12%), betalactam antibiotics (12%) and cardiac stimulants (7%). There was a 
statistically significant association between the number of drugs and age, some 
diagnosis and the severity of illness parameters, respectively. Socio-economic status 
and sex was not associated with numbers of drugs. Three medication groups 
(cardiac stimulants, opioids and analgesics without opioids) showed a statistically 
significant association with the severity of illness parameters.  
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Conclusion 
The number of drugs applied in the first 24 hours was independently associated with 
age, diagnosis and severity of illness parameters but not with sex and socio-
economic factors. This indicates that in our setting children received the same 
intensity and quality of treatment, irrespective of their socio-economic background. 
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Introduction 
The number of drugs applied to a patient is an important parameter of medication 
safety. Especially in children drug use should occur cautiously as the frequency of 
unlicensed and off label drug prescriptions has been reported to be about 50 to 70%, 
depending on the method of analysis used and on the clinical setting [1]. However, 
the research focus should not only lie on drug use, but also on the severity and the 
prevalence of diseases. The paediatric intensive care unit (PICU) is a setting in which 
children are seriously ill and therefore multiple drugs have to be prescribed.   
The possibility that more care may also cause harm is somewhat unexpected and 
received little attention in the past [2]. Therefore, it is important to detect potential 
over treatment and to evaluate its reasons [3]. In intensive care units, patients 
receive twice as many drugs as patients in general care units and are therefore at 
high risk of an adverse drug event (ADE) or an adverse drug reaction (ADR) [4]. A 
previous meta-analysis reported that the number of drugs administered to children 
was a potential predictor for ADRs [5]. However, there was no difference in ADE and 
ADR rates in intensive care patients when adjusted for number of drugs used [3]. In 
neonatal intensive care, Warrier et al showed that Caucasian race, male sex, 
gestational age of less than 28 weeks and birth weight under 1000 g were risk factors 
for higher drug exposure [6]. In one study it has been recognised that the nature of 
the population under study affects patterns of drug utilisation, which in turn affects 
the nature and frequency of ADRs [7].  
Published data show that drug exposure among sick children is high. Arlanda et al [8, 
9] described extensive medication use in a neonatal intensive care unit population 
and reported that at least 15% of neonates were administered more than 10 drugs 
during their PICU stay. Another study found that the number of prescribed drugs was 
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highest in children aged less than two years [10]. The importance of a careful risk-
benefit assessments before any medicine is prescribed is crucial to improve the 
safety of pharmacological treatments [11].  
The aim of this study is to evaluate the association between the number and the 
profile of drugs applied in the first 24 hours of admission to PICU and socio-
demographic, diagnostic and severity of illness parameters. The analysis should 
provide information on patient-related factors correlating with and probably 
influencing drug prescriptions in the first 24 hours and during the further course of 
patients in paediatric intensive care. 
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Methods 
Study population and data source 
We performed a retrospective observational study to determine the association 
between the number and profile of drugs ordered in the first 24 hours of admission to 
the PICU at the children’s hospital in Zürich during April and December 2010 and 
demographic, severity of illness and diagnostic parameters. The PICU is divided into 
a general PICU (9 beds) and a cardiac PICU (9 beds).  
The study has been approved by the local Ethics Committee.  
All patients who were admitted to the PICU were eligible to be included into the 
study. Each readmission after 24 hours out of the PICU was considered a new and 
separate case. Demographic parameters (sex, age and weight) and factors relating 
to severity of illness (length of PICU stay, mechanical ventilation, Paediatric Index of 
Mortality 2 (PIM2) [12]) are surveyed by means of the minimal data set (MDSi) of the 
Swiss Society of Intensive care [13]. Information on drugs prescribed during PICU 
stay (according to the anatomical therapeutical chemical (ATC) classification), 
laboratory parameters (serum creatinine, albumine, aspartate-amino-transferase 
(ASAT), alanine-amino-transferase (ALAT), c-reactive protein (CRP)), main diagnosis 
(according to the Australian and New Zealand Paediatric Intensive Care (ANZPIC) 
Registry Diagnostic Codes [14]), were obtained from the electronic patient records or 
the order sheets. Only medication orders during the first 24 hours of PICU admission 
were included in this analysis. 
Age was categorised into five different age groups: neonates (0-4 weeks), infants (1-
12 months), toddlers (1-4 years), children (5-11 years) and adolescents (> 12 years).  
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The main diagnoses were categorised into the following groups: Airway, 
cardiovascular, gastrointestinal, infection, injury, miscellaneous, neurological, post 
procedural or renal. 
PIM Score was categorised into four different strata related to the expected risk of 
mortality in percent: category 1 (0-0.99%), category 2 (1.0%-9.99%), category 3 
(10%-49.99%) and category 4 (50%-100%) [13]. 
The socio-professional status of the parents was defined according to the 
classification of the Swiss Federal Office of Statistics [14]. Criteria for classification 
into different categories were occupation, professional position and education. On 
these criteria four groups were built: high, medium, low or unknown. Within couples, 
the higher status was considered as representative.  
Nationality was categorised into four different groups according to the most common 
nationalities of the patients in the PICU: Swiss, German, East European, others. 
Mother tongue was categorised into four different groups according to the most 
common languages spoken in the PICU-patients: German, other Swiss national 
language than German, East European, others.  
Number of drugs was defined as the number of different drugs that a study subject 
received during the first 24 hours of PICU admission. All drugs, also drugs on 
demand, were included in this analysis except total parenteral nutrition, lipids and 
dialysate. 
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Statistical analysis 
Demographic variables were summarized using descriptive statistics. Data were 
expressed as means with corresponding standard deviation (SD), as median and 
ranges, or as proportions (%). 
The independent association between the number of administered drugs during the 
first 24 hours of admission and the socio-demographic, diagnostic and severity of 
illness parameters (main diagnosis, PIM Score, mechanical ventilation, length of 
PICU stay) was estimated by using multivariate Poisson regression analysis.  
In a second step, we classified the most frequently administered drugs in sixteen 
different groups according to the ATC code step four. We then ran again a 
multivariate Poisson regression model including the medication groups and the 
factors PIM Score, mechanical ventilation and length of PICU stay. 
Statistical significance was defined as p ≤0.05. Risk ratios are presented with 95% 
CI. All of the data analysis were conducted using the software program SAS, version 
9.3 (SAS Institute, Inc, Cary, NC). 
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Results 
Characteristics of the patients 
We identified a total of 359 patient admissions during the study period, and we 
included 1751 medication orders during the first 24 hours of admission in this 
analysis. 185 (52%) patients were admitted to the general PICU, whereas 174 (48%) 
patients were admitted to the cardiac PICU. Table 1 shows the socio-demographic 
characteristics of the patients and their parents and the corresponding numbers of 
drugs. The distribution of the diagnostic categories with corresponding numbers of 
drugs is shown in table 2, and table 3 provides data regarding the severity of illness 
parameters with corresponding numbers of drugs. The mean length of PICU stay of 
all analysed patients was 6.5 days (SD 10.2 days, median 4 days, range 1-116 
days). 
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Table 1: Socio-demographic Characteristics  
 N % Number of drugs 
   Mean SD Median (Range) 
Age (in categories)  
Neonates 
 (0-4 weeks) 
92 26 3.11 2.17 
2.50 (1; 12) 
Infants 
 (1-12 months) 
88 24 4.84 2.49 
4.00 (1; 12) 
Toddlers 
(1-4 years) 
76 21 4.14 2.47 
4.00 (1; 15) 
Children 
(5-10 years) 
49 14 4.57 4.41 
3.00 (1; 25) 
Adolescents 
(>10 years) 
54 15 4.78 2.83 
4.00 (1; 12) 
Sex  
Male 205 57 4.37 3.23 4.00 (1; 25) 
Female 154 43 3.99 2.30 4.00 (1; 12) 
Nationality      
Swiss 262 73 4.16 2.80 3,50 (1; 19) 
German 15 4 4.27 1.98 4.00 (1; 8) 
Eastern European 49 14 4.63 3.90 4.00 (1; 25) 
Other 33 9 3.88 1.92 4.00 (1; 9) 
Mother tongue      
German 318 89 4.04 2.61 3.00 (1; 19) 
Swiss national language 
other than German 
12 3 5.42 2.87 
5.00 (1; 11) 
Eastern European 22 6 6.00 5.25 5.50 (1; 25) 
other 7 2 4.00 1.91 4.00 (2; 8) 
Socio- Professional 
status      
high 49 14 4.33 2.63 3.00 (2; 8) 
low 26 7 4.04 3.19 3.00 (1; 19) 
medium 175 49 4.33 3.04 4.00 (1; 11) 
unknown 109 30 3.98 2.64 3.00 (1; 25) 
 
Table 2: Distribution of diagnostic categories 
Main Diagnosis 
N % Number of drugs 
  Mean SD Median (Range) 
injury 18 6 3.00 2.14 2.00 (1; 7) 
cardiovascular 120 34 4.52 3.44 4.00 (1; 25) 
neurological 34 9 4.00 3.12 3.00 (1; 15) 
airway 35 10 3.77 2.65 3.00 (1; 11) 
renal 4 1 2.00 0.82 2.00 (1; 3) 
gastrointestinal 16 5 4.19 2.23 4.00 (1; 8) 
infection 2 1 4.50 0.71 4.50 (4; 5) 
miscellaneous 39 11 4.44 3.06 3.00 (1; 12) 
post procedural 80 23 4.40 2.19 4.00 (1; 12) 
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Table 3: Severity of illness parameter 
Mechanical  
Ventilation 
N % Number of drugs 
  Mean SD Median (Range) 
No 129 36 3.45 2.79 3.00 (1; 19) 
Yes 230 64 4.63 2.84 4.00 (1; 25) 
PIM Score  
Category 1 
(0-0.99%) 
124 35 4.06 2.61 3.00 (1; 12) 
Category 2 
(1-9.99%) 
199 55 4.11 2.88 4.00 (1; 25) 
Category 3 
(10-49.99%) 
32 9 5.19 3.68 4.00 (1; 19) 
Category 4 
(50-100%) 
4 1 5.50 2.38 4.50 (4; 9) 
 
Most commonly ordered drug groups 
We analysed a total of 1751 medication orders throughout the study period. The 
patients received a median of 4 (range 1; 25) different drugs. The most frequently 
prescribed drug groups were analgesics other than opioids (19%), opioids (12%), 
betalactam antibiotics (12%) and cardiac stimulants (7%). 
 
Socio-demographic, diagnostic and severity of illness parameters associated with the 
number of drugs 
The results of multivariable Poisson regression analysis are presented in table 4. 
There was no statistically significant association between the number of drugs and 
the socio-demographic parameters except for age; the older the children the more 
drugs they received. However, the analysis showed a statistically significant 
difference in the number of drugs across patients with different principal diagnoses. 
Compared with the main diagnosis injury, patients with a cardiovascular diagnosis 
were more likely (RR 1.35 [CI 95% 1.05; 1.86-]) to receive more drugs. Patients with 
the main diagnosis ‘post procedural’ or ‘miscellaneous’ also received more drugs 
compared to the injury patients (RR 1.36 (CI 95% 1.02; 1.84) and RR 1.49 (CI 95% 
1.11; 2.05), respectively). According to the Poisson regression analysis the number 
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of drugs showed a statistically significant association with the severity of illness 
parameters mechanical ventilation (RR 1.35 (CI 95% 1.21; 1.54)) and length of PICU 
stay (RR 1.01 (CI 95% 1.00; 1.01)), but not with the PIM Score. 
Table 4: Socio-demographic, diagnostic and severity of illness parameters associated with the number 
of drugs (multivariable regression analysis) 
 
Risk factors Risk ratio 95% CI p- value
Age    
Neonates 1 (reference)   
Infants 0.95 0.87; 1.32 0.351 
Toddlers 1.13 1.01; 1.25 0.050 
Children 1.01 1.0; 1.02 0.013 
Adolescents 1.07 0.98; 1.12 0.163 
Gender (f)    
male 1 (reference)   
female 0.94 0.84; 1.04 0.25 
Nationality     
Swiss 1 (reference)    
German 1.13 0.91; 1.42 0.270 
Eastern European 1,10 0.76; 1.57 0.618 
other 0,99 0.74; 1.31 0.938 
Socio professional 
status     
high 1 (reference)   
low 0.96 0.74; 1.23 0.748 
medium 1.03 0.88; 1.21 0.729 
unknown 0.88 0.73; 1.05 0.145 
Language     
german 1 (reference)   
Swiss national language 
other than German 0.93 0.62; 1.46 0.742 
Eastern European 1.56 0.98; 2.56 0.068 
other 1.50 0.92; 2.51 0.111 
Main diagnosis     
injury 1 (reference)    
cardiovascular 1.38 1.05; 1.86 0.024 
neurological 1.30 0.95; 1.80 0.103 
airway 1.13 0.83; 1.57 0.457 
renal 0.62 0.27; 1.23 0.211 
gastrointestinal 1.20 0.84; 1.73 0.320 
infection 1.20 0.54; 2.39 0.634 
miscellaneous 1.49 1.11; 2.05 0.011 
post procedural 1.36 1.02; 1.84 0.041 
Factors of illness 
severity    
PIM Score  
category 1 1 (reference)   
PIM Score  
category 2 0.91 0.81; 1.03 0,148 
PIM Score  
category 3 1.04 0.86; 1.26 0.660 
Mechanical 
ventilation 1.35 1.21; 1.54 <0.001 
Length of PICU stay 1.01 1.00; 1.01 <0.001 
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Medication groups and their association with severity of illness parameters 
In a second step we ran a multivariable Poisson regression model in which we 
evaluated the association between various drug groups and the severity of illness 
parameters. Sixteen different drug groups were analysed. Only three groups (cardiac 
stimulants, opioids and analgesics without opioids) showed a statistically significant 
association with the severity of illness parameters. Tables 5 to 7 show the results of 
these three groups. 
Table 5: Cardiac stimulants: association with severity of illness parameters 
Risk factors Risk ratio 95% CI  p- value 
PIM Score category 1 1 (reference)    
PIM Score category 2 2.1 1.15; 4.01 0.019 
PIM Score category 3 4.01 1.68; 9.68 0.002 
Mechanical ventilation 
Yes 1.93 1.08; 3.56 0.030 
Length of PICU stay 1.03 1.01; 1.06 0.018 
 
Table 6: Opioids: association with severity of illness parameters 
Risk factors Risk ratio 95% CI  p- value 
PIM Score category 1 1 (reference)    
PIM Score category 2 1.37 1.27; 4.14 0.002 
PIM Score category 3 1.54 1.27; 7.54 0.007 








Length of PICU stay 0.98 0.95; 1.00 0.106 
 
Table 7: Analgesics without opioids: association with severity of illness parameters 
Risk factors Risk ratio 95% CI  p- value 
PIM Score category 1 1 (reference)    
PIM Score category 2 1.43 1.26; 5.05 < 0.000 
PIM Score category 3 1.15 1.08; 16.61 < 0.000 








Length of PICU stay 0.99 0.97; 1.01 0.320 
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Discussion 
Our study provides useful information on the number and type of drugs ordered 
during the first 24 hours of admission, and on socio-demographic, diagnostic and 
severity of illness parameters. Our data showed that the number of drugs was 
associated with age, diagnosis and certain severity of illness parameters, but not with 
sex or with socio-economic factors.  
The results of this study further provide evidence that the likelihood of receiving a 
larger amount of drugs was higher if the patient had a cardiovascular, a post 
procedural or ‘miscellaneous’ diagnosis. These findings are interesting in light of a 
previous study by Costa G et al. [17] who reported that the risk of death increased 
four-fold by adding a drug with cardiac and/or vascular effect. Postoperative patients 
are also likely to have sedatives and analgesics which would put them to risk for 
ADRs.  
As mechanical ventilation and length of PICU stay were both independently 
associated with a higher number of drugs (RR 1.35 (CI 95% 1.21; 1.54), RR 1.01 (CI 
95% 1.00; 0.01) respectively) during the first 24 hours, the question arises whether a 
certain over-treatment may play a role. Importantly, in our multiple regression 
equation, we corrected for illness severity at admission (expected mortality) and for 
diagnosis. A patient exposed to more drugs in the first 24 hours may need to stay 
longer in PICU because of drug-related problems. We previously showed that the 
number of drugs was independently associated with mortality [15]. There is a certain 
risk that ADEs are treated with additional drugs. Previous studies showed a 
relationship between the number of drugs prescribed and the occurrence of ADRs [5, 
18, 19]. Rashed A et al. [18] reported that patients with five or more drugs prescribed 
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during their hospital stay had a three times higher risk of developing ADRs compared 
to patients receiving one to four drugs. In our study, patients received a median of 
four (range 1; 25) different drugs. According to the literature, the drug combinations 
which are most often associated with ADRs are analgesics, antibiotics and opioids 
[20-22]. These drug groups were also most commonly prescribed to our study 
population. Therefore, it is important for physicians and pharmacists to be vigilant 
about these drug groups, especially in severely ill children. Careful evaluation of the 
indication of each drug should be a mandatory part of the prescribing and dispensing 
routine on the ward.  
Regarding the association between the number of drugs and socio-demographic 
parameters (nationality, language and professional status), we could not find any 
statistically significant association. These findings are in line with some previous 
studies [23-25] reporting that applied medical resources did not differ according to 
race, gender and insurance. In contrast, there are studies which have documented 
an association between low household income or low parents’ education and 
increased drug prescription in their children [26-28]. Ciofi degli Atte ML et al. [29] 
found that it is likely that paediatricians may be more cautious in prescribing drugs to 
a child with a highly educated mother, because she might be better informed about 
the potential side effects of drugs, thus resulting in paediatricians’ feeling to be more 
pressured with regard to the appropriateness of the prescription. On the other hand, 
a study on diagnostic and treatment behaviour in children with chronic respiratory 
symptoms in the UK pointed in the opposite direction: in the least deprived areas, 
children without significant asthma symptoms were more likely to be on inappropriate 
medication [30]. In accordance to the findings in the present study, we showed in a 
previous study that once children enter tertiary health care, such as intensive care, 
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nationality and socio-economic factors no longer influence quality of health care 
delivery [31]. This suggests that the socio-professional status may have an influence 
on primary care, but not on drug treatment patterns in the PICU. PICU-admission 
represents a critical status of illness severity, in which differences in nationality or 
socio-professional status may not play a role.  
Overall there were more male (57%) than female (43%) patients on our PICU. This 
gender distribution has been reported in other studies [11, 17, 25, 29]. In addition, in 
adult intensive care, it has been shown that men received an increased level of care 
[32]. Despite these differences, men did not have a better outcome [32]. Regarding 
the association between number of drugs and gender in PICU, a study reported a 
positive correlation between drug exposure and male gender [6]. In our study 
population, however, there was no evidence for a statistically significant difference 
between the numbers of drugs across gender. 
When looking at the age in the multivariable Poisson regression model, the RR 1.13 
(CI 95% 1.01; 1.25) for the age group ‘toddlers’, and the RR 1.01 (CI 95% 1.01; 1.02) 
for the age group ‘children’ indicated that older children were at a slightly increased 
likelihood of receiving more drugs than younger children. Similar findings were 
reported from other studies which revealed that older children had a tendency to 
have higher ADR frequency [11, 33]. However, these findings should be interpreted 
with caution. As we know, the pharmacokinetics and pharmacodynamics are 
particularly different in neonates and very young children. Warrier et al. [6] showed 
that especially male gender, gestational age under 28 weeks and birth weight under 
1000 g were risk factors for higher drug exposure. The question remains whether the 
nature of the drug which is given to the children is more important rather than the 
age.  
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Limitations 
This study has several limitations. First, the retrospective and observational approach 
depends on documentation by the clinical team and is therefore partly subjective. 
Second, we conducted this study in a general and cardiac PICU at a university 
hospital, so our results may have limited generalizability to non-academic PICUs. 
Third, possible misclassification of diagnoses and incomplete patients’ records can 
not be ruled out entirely and has to be considered in the interpretation of the data. 
Conclusion 
In the current PICU-population, the number of drugs applied in the first 24 hours was 
independently associated with age, diagnosis and the severity of illness parameters 
‘mechanical ventilation’ and ‘length of PICU-stay’, but not with sex and socio-
economic factors. The association with the need of mechanical ventilation and length 
of stay may be compatible with the deleterious effects of overtreatment, but it may 
also reflect higher disease severity of these children requiring a more intense 
tretament. The most inflicted drug groups were analgesics, opioids and cardiac 
stimulants. 
 We did not find an association between drug exposure and socio-economic status 
and sex, indicating that in our setting children received the same intensity and quality 
of treatment, irrespective of their socio-economic background. This is in agreement 
with previous studies in tertiary health care, whereas in primary care inequalities of 
care may exist. 
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5 Conclusions 
Our studies reveal different risk factors associated with the administration of drugs in 
children. With a view to reduce these risk factors and improve patient safety, the data 
presented here help us to prevent errors before they occur. In addition, prevention of 
DRPs requires a team approach, where clinical pharmacists play an important role in 
optimizing drug therapy in critically ill children. Careful evaluation of each drug, 
precise prescription and the awareness of the most vulnerable population may 
improve patient’s outcome.  
Medication associated with acute kidney injury 
AKI is an important risk factor for poor outcome in critically ill children [1]. In previous 
studies, medication exposure has been shown to be associated with the 
development of AKI [2-5]. Although the exact percentage of medication associated 
AKI is not known our case-control study reveals some critical medication groups 
which are independently associated with AKI. Medications that can cause kidney 
injury include betalactam antibiotics, glucocorticoids, opioids and NSAIDs. Careful 
monitoring especially of these drug groups is necessary because early recognition of 
drug-induced renal dysfunction may alleviate some of the morbidity and mortality that 
is associated with AKI in the PICU.  
However, in our opinion, it is also important to underline the multifactorial origin of 
AKI. Our results emphasize the complexity of AKI development. Measures of illness 
severity such as high PIM score, mechanical ventilation and length of stay are 
additional independent risk factors of AKI in the PICU. This means, that special focus 
should be given on the management of these patients. Whereas the severity of 
illness cannot be prevented in most instances, effects from drug treatment may be 
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more amenable to intervention. Thus, whenever possible, preventive measures 
should be instituted and medications should always be evaluated when renal 
dysfunction is identified.  
Analysis of medication prescribing errors 
The main focus of this thesis was to identify risk factors for MPEs and to determine 
the frequency, the types and the severity of these errors. Our analysis revealed that 
the incidence of prescribing errors was 14% of all prescriptions in our PICU. This is 
higher than in an adult study [6], but similar to published data in children [7, 8]. It was 
not surprising that dosing errors (overdosing or underdosing) were the most frequent 
errors as for most drugs, dosing calculations are required. In view of the importance 
of the MPEs and especially dosing errors, it seems to be necessary to strengthen the 
presence of a clinical pharmacist in the PICU as a key element in preventing 
prescribing errors. When assessing the effects of pharmacist’s interventions on 
prescribing error rates, the severity of errors should also be considered [9, 10]. 
Because the estimation of severity of our MPEs was sometimes difficult, it would be 
helpful to establish a method of measuring severity with acceptable international 
reliability and validity [11]. According to our study, special attention and precautions 
are appropriate when antihypertensives, antimycotics, drugs for nasal preparation, 
antiasthmatics, antibiotics and analgesics are administered. These drug groups 
accounted for 67% of the MPEs. In addition and not very surprisingly, long PICU stay 
and the need of long mechanical ventilation were additional risk factors for MPEs.  
Thus, analysis and publication of MPEs are essential requirements for the 
development and implementation of a long-term strategy of quality improvement. 
Additionally, clinical pharmacist involvement is desirable in the prescribing process. 
Even in settings with less resources, a clinical pharmacist can play an important role 
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in enhancing medication safety, particularly in paediatric patients where calculations 
are often more complex.   
Drugs and their association with socio-demographic, diagnostic and severity of 
illness parameters 
The last part of this thesis focused on the number and profile of ordered drugs 
applied in the first 24 hours of admission to PICU which is also an important issue of 
medication safety. The identification of patient related factors associated with the 
number of drugs could help to improve patient’s safety in the prescribing process. 
Longer PICU stay and the need of mechanical ventilation were associated with a 
larger number of drugs in the first 24 hours. Polypharmacy may increase ADRs and 
consecutively PICU stay [12, 13].Thus, it is important to review drug utilisation to 
identify drugs with increasing use. In our PICU particularly analgesics, opioids and 
cardiac stimulants should be kept in mind because they were associated with a 
longer PICU stay and mechanical ventilation. The study revealed also, that the types 
of main diagnosis such as cardiovascular and post procedural were independent 
predictors for a larger number of drugs. According to Costa G et al. [14] the risk of 
death increased four-fold by adding a drug with cardiac and/or vascular effect.  
These findings indicate that in order to optimise patient’s safety, healthcare 
professionals should keep the number of prescribed drugs as low as possible and 
pay particular attention to children at risk, such as long stay patients, patients with 
the need of mechanical ventilation and children with some critical main diagnoses. 
studies reveal different risk factors associated with the administration of drugs. With a 
view to reduce these risk factors and improve patient safety, the data presented here 
help us to prevent errors before they occur. In addition, prevention of DRPs requires 
a team approach, where clinical pharmacists play an important role in optimizing drug 
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therapy in critically ill children. Careful evaluation of the indication of each drug, 
precise prescription and the awareness of the most vulnerable population may 
improve patient’s outcome.  
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